Literature DB >> 23667766

Narcotic bowel syndrome: is it more common than before?

Palaniappan Manickam1, Abdulhassan Saad.   

Abstract

Entities:  

Year:  2013        PMID: 23667766      PMCID: PMC3644671          DOI: 10.5056/jnm.2013.19.2.273

Source DB:  PubMed          Journal:  J Neurogastroenterol Motil        ISSN: 2093-0879            Impact factor:   4.924


× No keyword cloud information.
TO THE EDITOR: We read the recent article Farmer et al1 on narcotic bowel syndrome (NBS) with great interest. The authors have comprehensively described a case of NBS along with the exciting pathophysiology. It further illustrates the common vicious cycle we see in daily clinical practice: a patient with chronic abdominal pain being prescribed opiates, which further worsens the pain and thereby escalating opiate dosage which produces a paradoxical effect. We would like to share some comments on the article. Previous reports have shown that approximately 6% of patients taking narcotics will develop NBS chronically.2 However, due to increased recognition of these cases, it might be more common than previously thought. The success of the detoxification regimen used for NBS could be short term as we have seen in our patient population. Though patients respond significantly in the initial weeks, most of the patients experience recurrent symptoms in a span of 2-3 months leading to a high recidivism rate. Furthermore, the authors mention that constipation may develop with opiate withdrawal and laxatives maybe used in the absence of an obstruction. However, it is usually diarrhea that is predominant in these patients in the acute phase of opioid withdrawal.3 In addition, when patients on chronic opioids present with severe constipation, abdominal discomfort and post-prandial emesis, the possibility of generalized gastroparesis should be in the differential for the work up of these patients.4 A trial of prokinetic drugs could be helpful in this subset of population before the use of selective opioid antagonist such as methylnaltrexone.
  4 in total

Review 1.  Management of drug and alcohol withdrawal.

Authors:  Thomas R Kosten; Patrick G O'Connor
Journal:  N Engl J Med       Date:  2003-05-01       Impact factor: 91.245

Review 2.  American Gastroenterological Association technical review on the diagnosis and treatment of gastroparesis.

Authors:  Henry P Parkman; William L Hasler; Robert S Fisher
Journal:  Gastroenterology       Date:  2004-11       Impact factor: 22.682

3.  Diagnosis, characterization, and 3-month outcome after detoxification of 39 patients with narcotic bowel syndrome.

Authors:  Douglas A Drossman; Carolyn B Morris; Hollie Edwards; Christina Ed Wrennall; Stephan R Weinland; Ademola O Aderoju; Renuka R Kulkarni-Kelapure; Yuming J Hu; Christine Dalton; Megan H Bouma; Joseph Zimmerman; Ceciel Rooker; Jane Leserman; Shrikant I Bangdiwala
Journal:  Am J Gastroenterol       Date:  2012-06-19       Impact factor: 10.864

4.  Opioids and the gastrointestinal tract - a case of narcotic bowel syndrome and literature review.

Authors:  Adam D Farmer; Ella Ferdinand; Qasim Aziz
Journal:  J Neurogastroenterol Motil       Date:  2013-01-08       Impact factor: 4.924

  4 in total
  2 in total

1.  Avoiding analgesic escalation and excessive healthcare utilization in severe irritable bowel syndrome: a role for intramuscular anticholinergics?

Authors:  James S Pearson; Christine Pollard; Peter J Whorwell
Journal:  Therap Adv Gastroenterol       Date:  2014-11       Impact factor: 4.409

Review 2.  The narcotic bowel syndrome: a recent update.

Authors:  Douglas Drossman; Eva Szigethy
Journal:  Am J Gastroenterol Suppl       Date:  2014-09-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.